NCT06760208 - A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market | Biotech Hunter

Enrollment

660

Participants

Timeline

Start Date

November 28, 2025

Primary Completion Date

October 30, 2028

Study Completion Date

October 30, 2028

Conditions

Pneumococcal ImmunizationSafety

Interventions

BIOLOGICAL

Pneumococcal 20-valent conjugate vaccine

For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be administered intramuscularly, preferably in the deltoid muscle, with care to avoid injection into or near nerves and blood vessels.

Trial Locations (1)

Unknown

Pfizer Korea, Seoul